How the protein LSD1 helps small cell lung cancer develop neuroendocrine features
Mechanisms by which LSD1 Promotes Neuroendocrine Differentiation and Small Cell Lung Cancer
This project aims to find why some small cell lung cancers respond to drugs that block the protein LSD1 and how to make those drugs work for more patients.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11228387 on NIH RePORTER |
What this research studies
Researchers will study small cell lung cancer cells and tumor samples to see how LSD1 controls cancer behavior and neuroendocrine features. They will use gene‑editing tools (like CRISPR) and drug testing in the lab to find genes that make tumors sensitive or resistant to LSD1 blockers. The team will map which genes LSD1 binds and represses and look for biomarkers that predict drug response. They will also test drug combinations in models to find ways to overcome resistance.
Who could benefit from this research
Good fit: People with small cell lung cancer, especially those considering participation in LSD1 inhibitor trials or who can provide tumor samples for research, are the most relevant candidates.
Not a fit: Patients without small cell lung cancer or whose tumors lack the molecular features targeted by LSD1-based approaches are unlikely to benefit from this line of work.
Why it matters
Potential benefit: If successful, this work could identify tests to predict who will benefit from LSD1 inhibitors and suggest drug combinations that help more patients with small cell lung cancer.
How similar studies have performed: Preclinical studies have shown some small cell lung cancers are highly sensitive to LSD1 inhibitors and early clinical trials are underway, but most tumors remain resistant.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Oser, Matthew Gilbert — Dana-Farber Cancer Inst
- Study coordinator: Oser, Matthew Gilbert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.